CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AnnJi Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AnnJi Pharmaceutical Co Ltd
B405
No.18, Siyuan St., Zhongzheng District
Phone: +886 223655677p:+886 223655677 TAIPEI, 115  Taiwan Ticker: 77547754
Business Summary
AnnJi Pharmaceutical Co Ltd is a Taiwan-based company mainly focuses on innovative new drug projects with high chances of success, and concentrates resources on the development of three main axes, including nuclear factor E2-related factor 2 (Nrf2) activator (AJ201), highly selective histone deacetylase 6 (HDAC6) inhibitor (AJ302), and next-generation androgen degradation promoter (AJ202). AJ201 oral suspension is used to treat neurodegenerative diseases caused by polyglutamine (polyQ), among which spinal and bulbar muscular atrophy (SBMA) is the first disease to be verified by clinical concept. AJ302 sustained-release injection is used to treat peripheral neuritis caused by chemotherapy. AJ202 scalp topical is used to treat male pattern baldness. Its products are mainly sold to European and American markets.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager WenyingHuang
Director RongyiHuang
Director ZhilongShen
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 34 (As of 12/31/2023)
Outstanding Shares: 93,574,539 (As of 6/30/2024)
Stock Exchange: TPO
Fax Number: +886 223658022


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024